Company intelligence / Profile preview
Poolbeg Pharma
London, N/A, United Kingdompoolbegpharma.com ↗
- Ownership
- Public · POLB
- Employees
- ~15
- Development stage
- Other
01
Overview
Lead program POLB001 has completed or is undergoing Phase I trials for CRS/severe influenza. Other programs include an oral GLP‑1R agonist for obesity/diabetes, a broad-spectrum RNA-based therapy for respiratory viruses, an intramuscular melioidosis vaccine, plus AI-driven infectious disease programs. No pivotal efficacy results disclosed as of May 2025.
- Therapeutic areas
- Metabolic DisordersOncologyRare DiseasesInfectious Diseases
- Modalities
- Small molecules (e.g., POLB001)RNA-based immunotherapy (POLB002)Oral encapsulated GLP‑1 receptor agonistsIntramuscular vaccines
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Inlicensed technology partners for encapsulation/vaccine delivery platforms.
04
Financials
- Market cap
- $61.4M
- Total revenue
- $0
- Enterprise value
- $54.9M
Beyond the preview
Go deeper on Poolbeg Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Poolbeg Pharma.